Pfizer Inc. (NYSE:PFE) Shares Sold by Snowden Capital Advisors LLC

Snowden Capital Advisors LLC lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 41.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 134,718 shares of the biopharmaceutical company's stock after selling 97,289 shares during the period. Snowden Capital Advisors LLC's holdings in Pfizer were worth $3,574,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Parsons Capital Management Inc. RI increased its holdings in shares of Pfizer by 118.7% in the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after buying an additional 159,984 shares in the last quarter. Mcdonald Partners LLC increased its holdings in shares of Pfizer by 9.9% in the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock valued at $2,926,000 after buying an additional 9,963 shares in the last quarter. Merit Financial Group LLC increased its holdings in shares of Pfizer by 60.8% in the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock valued at $3,395,000 after buying an additional 48,397 shares in the last quarter. Bank of Jackson Hole Trust bought a new position in shares of Pfizer in the fourth quarter valued at $264,000. Finally, Amplius Wealth Advisors LLC increased its holdings in shares of Pfizer by 80.7% in the fourth quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company's stock valued at $1,242,000 after buying an additional 20,911 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research reports. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Trading Up 1.0%

NYSE PFE opened at $22.83 on Friday. The company has a market capitalization of $129.77 billion, a PE ratio of 16.19, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The firm's fifty day simple moving average is $23.65 and its 200-day simple moving average is $25.36. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.82 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.